Overview

Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)

Status:
Completed

Trial end date:
2013-04-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and effectiveness of MK-6096 in the treatment of painful diabetic neuropathy (PDN) in adults.

Phase:

Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.